A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Inclusion Criteria:

• Participant must have measurable disease as defined per RECIST version 1.1

• Has a histologically confirmed colorectal adenocarcinoma with metastatic orunresectable disease (Stage IV as defined by American Joint Committee on Cancer [AJCC] 8th edition)

• No prior systemic therapy for colorectal cancer (CRC) in the metastatic settingexcept for the induction treatment of first-line therapy. Note: Local regionaltreatment performed during induction systemic treatment is allowed

• Participants who have completed the first-line induction treatment, with an overallresponse of stable disease or better. The duration of induction treatment should becompleted within approximately 6 months. The first dose of study treatment needs tooccur within 2 weeks (for 2-week regimen) or 3 weeks (for 3-week regimen) to 6 weeksafter Day 1 of the last cycle of induction therapy

Exclusion Criteria:

• Participants whose disease has become resectable at the investigator's discretionduring or after induction treatment are not eligible

• Progressive disease occurred less than 6 months from completion of any priorneoadjuvant therapy (ie, chemotherapy with or without radiotherapy) or adjuvanttherapy (ie, chemotherapy with or without radiotherapy), whichever occurred later

• Participants who have been treated with anti-epidermal growth factor receptor (EGFR)antibody in the induction treatment

• Any prior therapy targeting T-cell stimulation or checkpoint pathways

• Participants with B-raf proto-oncogene, serine/threonine kinase (BRAF)V600Emutations

• Have locally or centrally confirmed microsatellite instability-high (MSI-H) bypolymerase chain reaction (PCR) method or dMMR by immunohistochemistry (IHC) method

Note: Other protocol defined criteria may apply.